Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00172159
Status:
UNKNOWN
Last Update Posted:
2010-06-23
First Post:
2005-09-12
Brief Title:
Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers
Status:
UNKNOWN
Status Verified Date:
2000-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
More and more colorectal surgeons believe that surgical resections of hepatic metastases from colorectal cancer is the only chance for cure of patients The five-year survival for patients with hepatic metastasis from colorectal cancer after surgical resection is approximately 30 However most hepatic metastases from colorectal cancer were inoperable With the progress of chemotherapy for example the combination of the 5-Fu leucovorin and oxaliplatin some surgeons advocated that approximately 20 of inoperable liver metastases will be converted to operable case thus providing the long-term survival for patients In this study we made a phase Ⅱ clinical trial regarding the use of the Folfox-4 regimens in the neo-adjuvant treatment of inoperable hepatic metastases Our aims is to evaluate the tumor response rate for this regimen the rate of resectability of liver metastases progression free survival and overall survival of patients In addition the difference between the reports from Western and Oriental countries will be analyzed We believe this study will provide new perspectives regarding the most beneficial treatment modalities for the patients with hepatic metastases from colorectal cancer
Detailed Description:
More and more colorectal surgeons believe that surgical resections of hepatic metastases from colorectal cancer is the only chance for cure of patients The five-year survival for patients with hepatic metastasis from colorectal cancer after surgical resection is approximately 30 However most hepatic metastases from colorectal cancer were inoperable With the progress of chemotherapy for example the combination of the 5-Fu leucovorin and oxaliplatin some surgeons advocated that approximately 20 of inoperable liver metastases will be converted to operable case thus providing the long-term survival for patients In this study we made a phase Ⅱ clinical trial regarding the use of the Folfox-4 regimens in the neo-adjuvant treatment of inoperable hepatic metastases Our aims is to evaluate the tumor response rate for this regimen the rate of resectability of liver metastases progression free survival and overall survival of patients In addition the difference between the reports from Western and Oriental countries will be analyzed We believe this study will provide new perspectives regarding the most beneficial treatment modalities for the patients with hepatic metastases from colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None